These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3409945)

  • 21. Primary chemosensitivity and secondary drug resistance of xenografted soft part sarcomas.
    Budach V; Budach W; Scheulen M; Czeglarski G
    Strahlenther Onkol; 1989 Jul; 165(7):535-6. PubMed ID: 2473534
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis.
    Dombernowsky P; Mouridsen H; Schütte J; Santoro A; Rouessé J; Somers R; Stewart W; Pinedo HM; von Oosterom A; Blackledge G
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S17. PubMed ID: 3815714
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years.
    Wall N; Starkhammar H
    Acta Oncol; 2003; 42(1):55-61. PubMed ID: 12665332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
    Demetri GD
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):22-6. PubMed ID: 8677444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of ifosfamide in paediatric soft tissue sarcomas.
    de Kraker J; Voûte PA
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S23-4. PubMed ID: 3815716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternatives to CYVADIC-combination therapy of soft tissue sarcomas.
    Hartlapp JH; Münch HJ; Illiger HJ; Wolter H; Jensen JC
    Klin Wochenschr; 1985 Nov; 63(22):1160-2. PubMed ID: 3841170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemotherapy for soft tissue sarcoma--current concepts and review].
    Umeda T; Ishii T; Hatakeyama K; Wakita H
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1937-44. PubMed ID: 8215466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
    Roguin A; Ben Arush MW; Higasi A; Kuten A
    Harefuah; 1996 Apr; 130(8):511-4, 584. PubMed ID: 8765870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
    Benjamin RS; Legha SS; Patel SR; Nicaise C
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S174-9. PubMed ID: 8453693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of neoadjuvant radiochemotherapy in undifferentiated soft tissue sarcomas].
    Stuschke M
    Strahlenther Onkol; 1994 Aug; 170(8):480-3. PubMed ID: 8085215
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical experience with the cytostatic drug ifosfamide].
    Ritter S; Schröder HJ
    Med Welt; 1977 Sep; 28(35):1395-1400. PubMed ID: 70737
    [No Abstract]   [Full Text] [Related]  

  • 35. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J; Kellner R; Seeber S
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
    Kawai A; Umeda T; Wada T; Ihara K; Isu K; Abe S; Ishii T; Sugiura H; Araki N; Ozaki T; Yabe H; Hasegawa T; Tsugane S; Beppu Y;
    J Orthop Sci; 2005 May; 10(3):258-63. PubMed ID: 15928887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cantwell BM; Carmichael J; Ghani S; Harris AL
    Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma.
    Mansi JL; Fisher C; Wiltshaw E; MacMillan S; King M; Stuart-Harris R
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1439-43. PubMed ID: 3181268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ifosfamide in soft tissue sarcoma.
    Zaidi SH; Iqbal Z; Mallick JA
    J Pak Med Assoc; 1990 Sep; 40(9):222-4. PubMed ID: 2123272
    [No Abstract]   [Full Text] [Related]  

  • 40. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
    Ridola V; Fawaz O; Aubier F; Bergeron C; de Vathaire F; Pichon F; Orbach D; Gentet JC; Schmitt C; Dufour C; Oberlin O
    Eur J Cancer; 2009 Mar; 45(5):814-8. PubMed ID: 19216070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.